-
2024-518267-35-00
4
2025-06-10
Blod cancer
-
2023-508196-36-00
4
2025-05-27
Follicular lymphoma
-
2024-515279-37-00
5
2025-04-17
Relapsed or Refractory and Lenalidomide exposed Multiple Myeloma
-
2023-509907-34-01
5
2025-03-10
acute ischemic stroke
-
2022-502877-41-01
9
2025-02-10
Pulmonary sarcoidosis with or without extrapulmonary manifestations
-
2024-520299-86-00
6
2025-01-22
Acute interstitial nephritis
-
2023-505232-36-00
5
2024-11-15
Essential thrombocythemia
-
2024-513360-25-00
11
2024-10-29
Any cancer with cutaneous malignancies
-
2024-515507-18-00
5
2024-10-09
Status epilepticus
-
2024-517672-38-00
5
2024-09-20
Infection
-
2022-502139-20-00
4
2024-09-09
Mucositis and systemical inflammation, which is a treatment-related co
-
2024-510633-17-00
5
2024-09-05
acute heart failure
-
2024-511009-50-00
4
2024-08-27
Precocious puberty
and overweight
-
2024-515001-26-00
6
2024-07-25
Blood poisoning in patients with renal failure treated with hemodialys
-
2023-507684-19-00
5
2024-07-24
FGFR+ Intermediate-risk Non-muscle Invasive Bladder Cancer
-
2022-502135-19-00
4
2024-07-18
Calcific Aortic Valve Stenosis
-
2022-501697-19-01
5
2024-06-18
Small Lymphocytic Lymphoma (SLL) / Untreated Chronic Lymphocytic Leuke
-
2023-507617-96-01
6
2024-02-14
Pyogenic vertebral osteomyelitis
-
2022-502514-86-00
1
2024-02-07
Myeloproliferative Neoplasms
-
2022-502500-75-00
6
2024-01-30
Atrial fibrillation
-
2023-503228-17-00
4
2023-11-06
Colorectal Cancer
-
2024-514291-41-00
4
2023-10-20
Pancreatic cancer
-
2022-500035-36-01
6
2023-09-14
Acute heart failure with pulmonary congestion
-
2024-513562-19-00
5
2023-08-30
End-Stage Kidney Disease